1. Introduction {#sec1}
===============

Central nervous system cancer accounts for 2.3% of all cancer-related mortality worldwide and the annual incidence is reported to be 35 per million individuals \[[@B1]\]. As the most prevalent type of central nervous system cancer, glioma comprises nearly half of malignant brain cancers in adult population \[[@B2], [@B3]\]. Glioma can be categorized into grades I to IV pathologically according to the World Health Organization (WHO) grading system, and the majority belongs to grade IV, which is known as the most deadly type \[[@B4], [@B5]\]. In spite of currently available treatment strategies such as surgical resection, adjuvant radiotherapy, and combined radio-chemotherapy, the prognosis of glioma remains pessimistic with its 5-year survival rate being only 2% to 10% \[[@B6], [@B7]\]. Therefore, identification of prognostic factors is important to clinical decision for proper treatment modality and improvement of long-term outcome.

Advances in studies of genetic biomarkers, such as microRNAs (miRs), have promoted the application of biomarkers in the prognosis of glioma. miRs are a group of short and noncoding RNA molecules and have been identified as the regulators of gene expression \[[@B8]\]. They can work as tumor-suppressing genes as well as oncogenes and thus mediate the progression of cancers \[[@B9]--[@B11]\]. Studies show that miRs may be related to the prognosis of different cancers such as lung cancer, gastric cancer, and breast cancer \[[@B12]--[@B14]\]. Moreover, the relationships between different kinds of miRs, such as miRNA-15b \[[@B15], [@B16]\], 21 \[[@B17], [@B18]\], and 222 \[[@B19], [@B20]\], and prognosis of glioma have been investigated, while their results are conflicting due to the variability in study design, size of sample, or specimens. Additionally, no systematic review has been performed to explore the role of all pertinent miRs in evaluating glioma prognosis as a whole. In this study, relevant literatures investigating the relationship between numerous kinds of miRs and glioma were systematically reviewed, and pooled results were quantitatively analyzed to evaluate the prognostic value of different miRs in glioma.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

The meta-analysis was conducted in line with the recommendations of Meta-Analysis of Observational Studies in Epidemiology group (MOOSE) \[[@B21]\] and Preferred Reporting Items for Systematic Reviews and Meta-Analysis: The PRISMA Statement \[[@B22]\]. Three databases including PubMed, Embase, and Cochrane Library were searched for studies examining the relationships between miRs and prognosis of glioma by two authors (Danfeng Zhang and Qiang Xue) independently on August 8^th^, 2017 without date limit. We restricted the language to English. The Mesh terms were defined as "microrna/micrornas/mirna/miRs" with "gliomas/glial cell tumor/glioblastoma" in the search process. The reference lists of retrieved articles were also checked for pertinent literatures. The complete search strategy for PubMed and Cochrane Library was presented in Supplementary Material.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

Studies were included in this meta-analysis if they (1) recruited patients of glioma; (2) measured the expression of miRs in tumor tissue, serum, or plasma, as well as the survival prognosis of patients; (3) reported the survival curves for overall survival (OS) or disease-free survival (DFS) or cause-specific survival (CSS) or recurrence-free survival (RFS) with or without the hazard ratio (HR) and its 95% confidence intervals (CIs).

2.3. Exclusion Criteria {#sec2.3}
-----------------------

We excluded studies if (1) they were letters, reviews, or experimental studies; (2) the number of articles examining the relationship between miRs and glioma was less than three; (3) the original data could not be pooled. If one cohort was reported in two or more articles, we included the study most fully adjusted in order to prevent the disturbance of confounders.

2.4. Data Extraction and Quality Assessment {#sec2.4}
-------------------------------------------

Study characteristics and original data were collected by three authors (Yanming Zhang, Qiang Xue, and Jigang Chen), including first author\'s name, publication year, study design, study population, size of population, age and sex of participants, follow-up duration, type of sample, method of measuring miRs expression, and HRs and their 95% CIs. If HRs and 95% CIs were not reported in the included articles, we estimated them from Kaplan-Meier survival curves with methods described by Tierney et al. using Engauge Digitizer version 4.1 \[[@B23]\]. If only HRs and P values were reported, we estimated the 95% CIs using previously described method \[[@B24]\].

Studies were included according to the following checklist on the basis of the criteria provided by MOOSE group \[[@B21]\]: clearly defined study design; clearly described study population (country); sufficiently large sample (N\>30); clearly described outcome (OS, CSS, DFS, or RFS); clear defined miRs measurement, including quantitative real-time polymerase chain reaction (qRT-PCR) or in situ hybridization (ISH); clear definition of cut-off values; miRs measurement in tumor tissue, plasma, or serum; sufficiently long follow-up. Studies were excluded if they did not meet these criteria. Quality of included studies was systematically evaluated according to Newcastle-Ottawa Scale by two reviewers (Liang Zhao and Danfeng Zhang) independently \[[@B25]\]. Disagreement was solved by joint review.

2.5. Statistical Analysis {#sec2.5}
-------------------------

HRs and their 95% CIs extracted from studies were pooled using Stata version 12.0 (StataCorp, College Station, Texas, USA) and random-effects model. We used Chi-square test and*I*^*2*^ statistic in the assessment of heterogeneities among studies, and*I*^*2*^ values of \<40%, 40%-75%, and \>75% were defined as low, moderate, and high, respectively \[[@B26]\]. Subgroups analysis was conducted according to the type of survival prognosis (OS versus DFS) and data sources (direct extraction versus calculation from HR and P versus calculation from survival curve). In the pooled analysis, Egger\'s test was employed in the analysis of publication bias. Sensitivity analysis was conducted by the removal of individual study by turns. P\<0.1 was considered as significant in the analysis of publication bias and heterogeneity, while a significant level of 0.05 was used in other analyses.

3. Results {#sec3}
==========

3.1. Study Selection {#sec3.1}
--------------------

The study selection process was shown in [Figure I](#supplementary-material-1){ref-type="supplementary-material"} of Supplementary Material. A total of 2470 records were available in the initial search, including 1160 records from PubMed, 1294 from Embase, and 16 from Cochrane Library. 1837 studies remained for full texts review after removing the duplicates and reviewing the abstract. No eligible study was detected by screening the reference lists. Finally, 31 studies met the inclusion criteria and were included in our meta-analysis.

3.2. Study Characteristics {#sec3.2}
--------------------------

The quality assessment of each study was shown in [Table I](#supplementary-material-1){ref-type="supplementary-material"} of Supplementary Material. The number of literatures evaluating the association between miRs and the prognosis of glioma were listed in [Table II](#supplementary-material-1){ref-type="supplementary-material"} of Supplementary Material. The main characteristics of included articles were described in [Table 1](#tab1){ref-type="table"}. All of them were retrospective and published between 2010 and 2017. A total of 4708 glioma patients were evaluated for the prognostic value of 15 different miRs, with a median sample size of 109 patients (range, 38--548 patients). Expression of miRs was mainly measured in tumor tissues, while four studies examined miRs in serum or plasma \[[@B30], [@B27], [@B28], [@B29]\]. Most studies used qRT-PCR to detect miRs, while three employed ISH and microarray \[[@B18], [@B31], [@B27]\]. HRs and 95% CIs were not reported in 14 studies \[[@B15], [@B16], [@B20], [@B40], [@B32], [@B35], [@B42], [@B33], [@B36], [@B37], [@B38], [@B34], [@B41], [@B39]\], and we estimated them by methods described above. The cutoff value was not reported in 11 articles \[[@B15], [@B18], [@B42], [@B30], [@B43], [@B45], [@B34]--[@B39], [@B44]\]. The reported HRs were adjusted for related variables such as pathological grade, Karnofsky performance score (KPS) and tumor size in nine studies \[[@B17]--[@B19], [@B46], [@B48], [@B47], [@B43], [@B27], [@B29]\] ([Table 1](#tab1){ref-type="table"}).

3.3. Meta-Analysis {#sec3.3}
------------------

The pooled HRs together with the heterogeneity for all miRs were demonstrated in [Table 2](#tab2){ref-type="table"}.

3.4. High Expression of miR-15b, 21, 148a, 196, 210, and 221 Predicts Poor Prognosis in Glioma Patients {#sec3.4}
-------------------------------------------------------------------------------------------------------

Five studies were included to investigate the relationship between high expression of miR-15b and DFS/OS \[[@B15], [@B16], [@B47], [@B33], [@B27]\]. The pooled results indicated that high miR-15b expression was significantly associated with the poor prognosis in glioma (HR, 1.584; 95% CI, 1.199-2.092, P=0.001, [Figure 1(a)](#fig1){ref-type="fig"}).

Six studies examined the prognostic value of miR-21 in glioma \[[@B17], [@B18], [@B48], [@B47], [@B33], [@B43]\], suggesting that miR-21 overexpression significantly predicted poor prognosis in glioma (HR, 1.591; 95% CI, 1.278-1.981, P\<0.001, [Figure 1(b)](#fig1){ref-type="fig"}).

Three literatures focused on the relationship between high expression of miR-148a and OS/DFS \[[@B32], [@B47], [@B44]\]. The summary results suggested that miR-148a was correlated with shorter DFS/OS (HR, 1.122; 95% CI, 1.023-1.231, P=0.015, [Figure 1(c)](#fig1){ref-type="fig"}).

Pooled results also demonstrated significant relationship between miR-196, 210, and 221 and poor prognosis in glioma (HR, 1.877; 95% CI, 1.033-3.411, P=0.039 for miR-196; HR, 1.251; 95% CI, 1.010-1.550, P=0.04 for miR-210; HR, 1.269; 95% CI, 1.054-1.527, P=0.012 for miR-221; Figures [1(d)](#fig1){ref-type="fig"}--[1(f)](#fig1){ref-type="fig"}).

3.5. Low Expression of miR-106a and 124 Predicts Poor Prognosis in Glioma Patients {#sec3.5}
----------------------------------------------------------------------------------

There were six \[[@B20], [@B48]--[@B31], [@B47], [@B27]\] and three \[[@B47], [@B27], [@B34]\] studies investigating the prognostic value of miR-106a and miR-124 in glioma, respectively. The summary HRs indicated these two miRs were negatively associated with poor prognosis in glioma (HR, 0.809; 95% CI, 0.655-0.998, P=0.048 for miR-106a; HR, 0.833; 95% CI, 0.729-0.952, P=0.007 for miR-124, Figures [2(a)](#fig2){ref-type="fig"}-[2(b)](#fig2){ref-type="fig"}).

3.6. No Significant Relationship between Overexpression of miR-10b, 17, 20a, 155, 182, 200b, and 222 and Poor Prognosis in Glioma Patients {#sec3.6}
------------------------------------------------------------------------------------------------------------------------------------------

Several different studies were included to examine the prognostic value of miR-10b, 17, 20a, 155, 182, 200b, and 222 in glioma. However, pooled HRs suggested no statistical relationships between these miRs and prognosis of glioma. The detailed results were illustrated in [Table 2](#tab2){ref-type="table"} and [Figure 3](#fig3){ref-type="fig"}.

3.7. Subgroups Analysis {#sec3.7}
-----------------------

In the subgroup of OS outcomes, we found high expression of miR-10b predicted poor prognosis in glioma patients (HR, 3.70; 95% CI, 2.40-5.70, P\<0.05) ([Table III](#supplementary-material-1){ref-type="supplementary-material"} in Supplementary Material). For data calculation from HR and P value, we detected that low expression of miR-17 and 20a was associated with poor prognosis in glioma patients (HR, 0.67, 95% CI, 0.56-0.79, P\<0.05 for miR-17; HR, 0.68, 95% CI, 0.57-0.80, P\<0.05 for miR-20a, [Table III](#supplementary-material-1){ref-type="supplementary-material"} in Supplementary Material). For data calculation from survival curve, overexpression of miR-10b and 182 was detected to be related to poor prognosis after glioma (HR, 3.42, 95% CI, 2.08-5.62, P\<0.05 for miR-10b; HR, 3.39, 95% CI, 1.98-5.80, P\<0.05 for miR-182, [Table III](#supplementary-material-1){ref-type="supplementary-material"} in Supplementary Material).

3.8. Publication Bias {#sec3.8}
---------------------

Publication bias was assessed for the meta-analysis of all miRs and we found no publication bias by Egger\'s test, which was shown in [Table 2](#tab2){ref-type="table"}.

3.9. Sensitivity Analysis {#sec3.9}
-------------------------

We have done the sensitivity analysis through removing studies one by one in the analysis of all miRs. Our results were roughly not altered suggesting that our pooled HRs and the 95%CIs were basically stable. However, when it went to miR-10b, the result turned to be significant, suggesting that high miR-10b expression was associated with the poor prognosis in glioma if we removed data from Chen et al.\'s article (HR, 1.428; 95% CI, 1.022-1.995, P=0.037) \[[@B47]\]. For miR-155, high miR-155 expression was associated with the poor prognosis in glioma (HR,1.22; 95% CI, 1.044-1.425, P=0.012) after removing Qiu et al.\'s study \[[@B46]\].

4. Discussion {#sec4}
=============

Mounting evidences have shown that various miRs are related to the survival outcome in glioma patients. However, different studies present with inconsistent conclusions. For example, three studies investigate the association between miR-10b and glioma prognosis, and the results are significant in Zhang et al. and Ji et al. \[[@B41], [@B49]\] and insignificant in Chen et al. \[[@B47]\]. Similar conflicting results are also demonstrated in researches exploring other miRs \[[@B13], [@B30], [@B50]--[@B52]\]. Therefore, it is crucial to perform current meta-analysis to have an overall understanding of relationships between miRs expression and prognosis of glioma patients.

A total of 15 miRs and their ability in predicting prognosis of glioma are investigated in this study. Patients with high levels of miR-15b, 21, 148a, 196, 210, and 221 expression have a statistically significant poorer DFS/OS than those with low expression levels. Contrastively, decreased expression of miR-106a and 124 is associated with poor prognosis in patients of glioma. There are some other miRs including miR-10b, 17, 20a, 155, 182, 200b, and 222 which are indicated to have no prognostic value in glioma. There is no publication bias after the assessment using Egger\'s test and the pooled HRs remain the same when removing studies one by one.

Among the miRs whose overexpression is indicated to be associated with poor DFS/OS, miR-21 is the first discovered microRNA and known to be widely expressed in human tissues. It is also the most studied tumor-related biomarkers and might play an essential role in many different cancers \[[@B53]\]. Increased expression level of miR-21 has been discovered to be related to dismal outcome in cancer patients \[[@B13]\]. miR-21 is indicated to be overly expressed in glioma in a WHO-grade specific manner \[[@B54]\]. Several literatures assure that miR-21 can induce the tumor growth, invasion, and migration and inhibit cell apoptosis \[[@B55], [@B56]\]. miR-21 has been identified to target at the tumor suppressing genes, such as the protein tyrosine phosphatase (PTEN), programmed cell death 4 (PDCD4), and B cell translocation gene 2 (BTG2). Inhibition of miR-21 would lead to the upregulation of these genes, which ultimately affect the cancer progression and prognosis \[[@B13], [@B60], [@B57]--[@B59]\].

Only two miRs (miR-106a and miR-124) are proved in this study that their downregulations are connected with poor prognosis. As a protective microRNA, miR-106a is located at Xq26.2 and the length of mature miR-106a is 23 nucleotides. Previous study has shown that miR-106a has a cancer suppressing effect through antiproliferation and inducing apoptosis in glioma cells. This effect might arise from E2F1 inhibition via posttranscriptional regulation \[[@B61]\]. Similarly, miR-124 is reported to have effects of tumor suppression via the regulation of cell proliferation, apoptosis, migration, and invasion in certain cancer diseases \[[@B64], [@B62], [@B63]\]. Study also indicated that miR-124 works through the inhibition of STAT3 signal to enhance the T cell mediated clearance of glioma cells \[[@B65]\].

The relationships between overexpression of seven miRs (miR-10b, 17, 20a, 155, 182, 200b, and 222) and DFS/OS for glioma patients were not proved in our study. This might attribute to the nature of miRs themselves. For example, miR-17 is extensively studied, and it proves to have both the tumor suppressing and oncogenic functions. Upregulation of miR-17 can promote cancer growth via aiming E2F1 and increase angiogenesis through thrombospondin-1 \[[@B66]\]. Contrastively, overexpression of miR-17 can also lead to the decreased cell migration and proliferation by the repressing of fibronectin expression \[[@B67]\]. Moreover, different sample size, type of specimens, and prognosis assessment might also produce the inconsistent conclusions which ultimately lead to the insignificant results in our meta-analysis. Summary of miRs along with altered expression and potential targets as well as pathways in this study is listed in [Table 3](#tab3){ref-type="table"}.

Though the measurement of miRs expression levels is a convenient way in predicting the glioma prognosis, difficulties still exist before applying miRs in the clinical settings. First, cell-free miRs would release from some normal human tissues as well and might interfere the final results to some degree \[[@B68]\]. Therefore, it is important to determine the source of tumor-specific miRs and create a method which could differentiate cancer population from healthy group. Second, no standard procedure for the measurement of miRs has been confirmed, which might be the source of contradictory results. Moreover, a single microRNA can be associated with different tumor tissues. For example, the prognostic value of miR-21 has been established among the patients of breast cancer \[[@B69]\], pancreatic ductal adenocarcinoma \[[@B70]\], and gastric cancer \[[@B71]\]. Therefore, a group of miRs specific to glioma is useful and might significantly improve the prognostic accuracy \[[@B72]\].

To our knowledge, though some meta-analyses regarding the prognostic value of several miRs in glioma patients have been published \[[@B30], [@B50]--[@B52]\], these studies are incomplete and avoid assessing some other available miRs. We include all of the miRs which have been explored previously, and a total of 15 miRs are investigated ultimately. Among these 15 miRs, eight of them have established the prognostic significance with glioma. However, relationship between the remaining miRs and prognosis of glioma patients should be validated by further large-scale prospective studies in future. Our study also has advantages in including the newly published trials from different places and times, which are representative enough.

Limitations of our meta-analysis should be noticed before interpreting the results. Firstly, as we mentioned above, there is no single microRNA which is specific to glioma exclusively, and the panel of miRs which can be used to distinguish glioma from other cancers and satisfactorily predict the prognosis has not been discovered yet. Therefore, the clinical application of miRs is restricted. Secondly, the heterogeneity among studies is generally significant. Thirdly, the prognosis is evaluated by different indicators, such as the overall survival and disease-free survival, which might be the source of heterogeneity. Fourthly, all the included literatures are retrospective and there lack relative high-quality trials. Lastly, the number of available studies is limited for some miRs and it might be insufficient to draw a definite conclusion.
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![Forest plots of miR-15b (a), 21 (b), 148a (c), 196 (d), 210 (e), and 221 (f) and glioma prognosis.](BMRI2019-4015969.001){#fig1}

![Forest plots of miR-106a (a) and 124 (b) and glioma prognosis.](BMRI2019-4015969.002){#fig2}

![Forest plots of miR-10b (a), 17 (b), 20a (c), 155 (d), 182 (e), 200b (f), and 222 (g) and glioma prognosis.](BMRI2019-4015969.003){#fig3}

###### 

Characteristics of articles with Kaplan-Meier survival curves in glioma.

  microRNA   Study                Country   Study design   Sample   Number   Stage   Cut-off           Follow-up (months)   Result   HR(H/L)   95%CI           p
  ---------- -------------------- --------- -------------- -------- -------- ------- ----------------- -------------------- -------- --------- --------------- ---------
  10b        Ji, Y 2015           China     R              Frozen   95       I-IV    Median            60                   OSm      4.71      1.45-8.32       \<0.001
  10b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.09      0.98-1.21       0.12
  10b        Zhang, X 2016        China     R              Frozen   128      I-IV    None              80                   OSu      3.42      2.08-5.62       \<0.001
  10b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.30      0.53-3.2        0.58
  10b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.06      0.97-1.15       0.18
  15b        Guan, Y 2010         Japan     R              Frozen   39       I-IV    Mean              \>60                 OSm      1.87      0.68-5.16       0.227
  15b        Pang, C 2015         China     R              Frozen   76       II-IV   None              \>60                 OSu      5.68      2.81-11.50      \<0.001
  15b        Sun, G 2015          China     R              Frozen   92       I-IV    Median            \>60                 OSu      2.21      1.36-3.6        0.001
  15b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.67      0.51-0.87       0.003
  15b        Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      0.76      0.40-1.52       0.028
  15b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.80      0.65-0.99       0.04
  15b        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.76      0.63-0.91       0.003
  17         Lu, S 2012           China     R              Tissue   108      I-IV    Median            \>100                OSm      2.14      1.06-4.30       0.034
  17         Sun, C 2017          TCGA      R              Tissue   548      I-IV    Median            130                  OSu      0.6517    0.50-0.85       0.002
  17-5b      Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.934     0.76-1.16       0.54
  17-5b      Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      1.7       1.05-4.01       0.043
  17-5b      Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.16      0.95-1.42       0.15
  17-5b      Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.01      0.80-1.28       0.94
  17-5p      Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      0.68      0.54-0.85       0.0008
  20a        Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      0.68      0.55-0.84       \<0.001
  20a        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.95      0.79-1.14       0.59
  20a        Sun, C 2017          TCGA      R              Tissue   548      I-IV    Median            130                  OSu      0.6708    0.51-0.88       0.005
  20a        Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      1.69      1.06-3.79       0.04
  20a        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.05      0.87-1.27       0.63
  20a        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.93      0.80-1.08       0.35
  21         Guan, Y 2010         Japan     R              Frozen   39       I-IV    Mean              \>60                 OSm      0.57      0.21-1.52       0.264
  21         Hermansen, S 2012    Denmark   R              FFPE     189      I-IV    None              \>60                 OSm      1.545     1.002-2.381     0.049
  21         Wu, L 2013           China     R              Frozen   152      I-IV    Mean              60                   OSm      3.17      2.39-4.179      \<0.001
  21         Barbano, R 2014      TCGA      R              Tissue   191      I-IV    None              \>110                OSu      1.26      1.06-1.48       0.007
  21         Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.73      0.58-0.91       0.006
  21         Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.54      0.37-0.80       0.002
  21         Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.72      0.56-0.92       0.009
  21         Zhi, F 2010          China     R              Tissue   124      I-IV    Median            100                  OSm      1.882     1.07-3.308      0.028
  106a       Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      0.66      0.52-0.83       \<0.001
  106a       Zhao, S 2013         China     R              FFPE     114      I-IV    Median            50                   OSm      0.504     0.297--0.854    0 .011
  106a       Zhao, S 2013         China     R              FFPE     103      I-IV    Median            50                   OSm      0.452     0.255--0.800    0 .006
  106a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.94      0.73-1.20       0.62
  106a       Sun, C 2017          TCGA      R              Tissue   548      I-IV    Median            130                  OSu      0.6341    0.47-0.85       0.003
  106a       Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      1.71      1.07-3.63       0.038
  106a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.96      0.80-1.15       0.67
  106a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.97      0.81-1.17       0.76
  106a       Zhi, F 2010          China     R              Tissue   124      I-IV    Median            100                  OSm      0.6139    0.34-1.11       0.108
  124        Chen, T 2015         China     R              Frozen   137      I-IV    None              60                   OSm      2.37      1.24-4.528      0.009
  124        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.19      1.06-1.33       0.003
  124        Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      0.65      0.26-1.03       0.062
  124        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.33      1.08-1.64       0.007
  124        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.23      1.11-1.36       \<0.001
  148a       Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      1.21      1.08-1.356      0.001
  148a       Kim, J 2014          TCGA      R              Tissue   482      I-IV    None              \>60                 OSu      1.19      1.10-1.29       \<0.001
  148a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.9       0.79-1.03       0.13
  148a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     2.44      0.77-7.74       0.13
  148a       Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.99      0.90-1.09       0.85
  155        Qiu, S 2013          TCGA      R              Tissue   480      I-IV    50th percentile   \>100                OSm      0.796     0.646-0.982     0.033
  155        Barbano, R 2014      TCGA      R              Tissue   191      I-IV    None              \>110                OSu      1.23      1.06-1.44       0.008
  155        Sun, J 2014          China     R              Tissue   131      I-IV    Mean              80                   OSu      2.05      1.35-3.12       \<0.001
  155        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.91      0.77-1.07       0.27
  155        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.70      0.18-2.73       0.62
  155        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.91      0.77-1.07       0.26
  182        Jiang, L 2010        China     R              FFPE     119      I-IV    Median            80                   OSm      3.39      1.98-5.80       \<0.001
  182        Xiao, Y 2016         China     R              Blood    112      I-IV    None              60                   OSm      1.25      0.89-2.53       0.013
  182        Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      0.6       0.29-0.92       0.037
  182a       Zhao, S 2013         China     R              FFPE     114      I-IV    Median            50                   OSm      0.974     0.611--1.554    0 .912
  182a       Zhao, S 2013         China     R              FFPE     103      I-IV    Median            50                   OSm      1.032     0.630--1.693    0 .900
  196        Guan, Y 2010         Japan     R              Frozen   39       I-IV    Mean              \>60                 OSm      3.37      1.20-9.46       0.021
  196        Lakomy, R 2011       Czech     R              FFPE     38       I-IV    Median            \>60                 OSu      0.547     0.2776-1.0776   0.049
  196a       Zhao, S 2013         China     R              FFPE     114      I-IV    Median            50                   OSm      2.252     1.321-3.841     0.003
  196a       Zhao, S 2013         China     R              FFPE     103      I-IV    Median            50                   OSm      1.906     1.108-3.281     0.021
  196a       Guan, Y 2015         China     R              Frozen   63       I-IV    None              \>60                 OSu      3.17      1.82-5.53       0.007
  200b       Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      1.21      1.067-1.372     0.003
  200b       Liu, Q 2014          China     R              Tissue   73       I-IV    None              40                   OSu      0.3       0.09-0.96       0.05
  200b       Men, D 2014          China     R              Frozen   266      I-IV    Median            60                   OSm      2.9       1.166-7.21      0.022
  210        Qiu, S 2013          TCGA      R              Tissue   480      I-IV    50th percentile   \>100                OSm      0.749     0.591-0.949     0.017
  210        Barbano, R 2014      TCGA      R              Tissue   191      I-IV    None              \>110                OSu      1.16      1.01-1.33       0.038
  210        Lai, N 2014          China     R              Frozen   125      I-IV    Mean              \>100                OSu      2.3       1.47-3.61       0.0003
  210        Lai, N 2015          China     R              Serum    126      I-IV    Mean              \>80                 OSm      3.84      2.09-7.08       \<0.001
  210        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.97      0.83-1.14       0.71
  210        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.53      0.20-1.43       0.21
  210        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.93      0.84-1.03       0.17
  221        Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      1.27      1.097-1.471     0.001
  221        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.92      0.79-1.06       0.26
  221        Li, X 2016           China     R              Tissue   45       I-IV    Mean              36                   OSu      2.18      1.02-4.65       0.044
  221        Zhang, R 2016        China     R              Blood    50       I-IV    None              50                   OSu      2.4       1.42-4.05       0.001
  221        Chen, Y 2017         China     R              Tissue   114      I-IV    None              72                   OSm      2.039     1.06-3.91       0.032
  221        Sun, C 2017          TCGA      R              Tissue   548      I-IV    Median            130                  OSu      0.6856    0.53-0.88       0.003
  221        Xue, L 2017          China     R              Tissue   165      I-IV    Median            60                   OSu      1.656     1.135-2.486     0.009
  221        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.80      0.19-3.30       0.77
  221        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.88      0.74-1.04       0.14
  222        Srinivasan, S 2011   TCGA      R              Tissue   111      I-IV    60th percentile   120                  OSm      1.26      1.11-1.43       0.0004
  222        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.04      0.92-1.18       0.53
  222        Li, X 2016           China     R              Tissue   45       I-IV    Mean              36                   OSu      2.13      1.01-4.48       0.043
  222        Zhang, R 2016        China     R              Blood    50       I-IV    None              50                   OSu      2.81      1.70-4.65       0.0004
  222        Chen, Y 2017         China     R              Tissue   114      I-IV    None              72                   OSm      0.899     0.559-1.447     0.661
  222        Sun, C 2017          TCGA      R              Tissue   548      I-IV    Median            130                  OSu      0.5947    0.44-0.81       0.001
  222        Zhao, H 2017         America   R              Serum    106      I-IV    Median            24                   OSu      1.71      1.07-3.63       0.038
  222        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     1.41      0.91-2.17       0.12
  222        Chen, W 2016         TCGA      R              Tissue   109      I-IV    Median            \>60                 DFSu     0.90      0.80-1.01       0.07

CI: confidence interval; DFS: disease free survival; FFPE: formalin-fixed paraffin-embedded; HR (H/L): hazard ratio (High/Low); OS: overall survival; R: retrospective; TGGA: The Cancer Genome Atlas; m: multivariate analysis; u: univariate analysis.

###### 

Summary of the HR for microRNA expression in glioma.

  microRNA   Survival analysis   Number of articles   Included references                                          HR      95%CI         P value   *∗*Heterogeneity   Total patients   Figure   Publication bias
  ---------- ------------------- -------------------- ------------------------------------------------------------ ------- ------------- --------- ------------------ ---------------- -------- ------------------
  10b        OS/DFS              3                    \[[@B40]--[@B48]\]                                           1.349   0.984-1.849   0.063     89.7%, p\<0.001    550              4A       0.16
  15b        OS/DFS              5                    \[[@B15], [@B16], [@B26], [@B46], [@B32]\]                   1.584   1.199-2.092   0.001     74.9%, p=0.001     640              2A       0.263
  17         OS/DFS              5                    \[[@B20], [@B26], [@B46], [@B31], [@B35]\]                   0.933   0.759-1.149   0.516     75.8%, p\<0.001    1200             4B       0.368
  20a        OS/DFS              4                    \[[@B20], [@B26], [@B46], [@B31]\]                           0.919   0.755-1.119   0.399     77.9%, p\<0.001    1092             4C       0.925
  21         OS/DFS              6                    \[[@B18], [@B46], [@B32], [@B42]--[@B72]\]                   1.591   1.278-1.981   \<0.001   82.6%, p\<0.001    1022             2B       0.536
  106a       OS/DFS              6                    \[[@B20], [@B26], [@B46], [@B31], [@B47], [@B30]\]           0.809   0.655-0.998   0.048     77.9%, p\<0.001    1433             3A       0.177
  124        OS/DFS              3                    \[[@B26], [@B46], [@B33]\]                                   0.833   0.729-0.952   0.007     66.6%, p=0.018     570              3B       0.516
  148a       OS/DFS              3                    \[[@B46], [@B31], [@B43]\]                                   1.122   1.023-1.231   0.015     60.5%, p=0.038     920              2C       0.254
  155        OS/DFS              4                    \[[@B46], [@B42], [@B36], [@B45]\]                           1.143   0.942-1.387   0.175     74.9%, p=0.001     1129             4D       0.586
  182        OS                  4                    \[[@B26], [@B30], [@B27], [@B37]\]                           1.206   0.709-2.051   0.489     81%, p\<0.001      554              4E       0.955
  196        OS                  4                    \[[@B32], [@B30], [@B38], [@B73]\]                           1.877   1.033-3.411   0.039     77.5%, p=0.001     357              2D       0.893
  200b       OS                  3                    \[[@B31], [@B34], [@B41]\]                                   1.113   0.451-2.744   0.816     77.5%, p=0.012     450              4F       0.923
  210        OS/DFS              5                    \[[@B46], [@B42], [@B45], [@B28], [@B39]\]                   1.251   1.010-1.550   0.04      84.7%, p\<0.001    1249             2E       0.181
  221        OS/DFS              7                    \[[@B19], [@B20], [@B46], [@B31], [@B29]--[@B74]\]           1.269   1.054-1.527   0.012     77.0%, p\<0.001    1360             2F       0.194
  222        OS/DFS              7                    \[[@B19], [@B20], [@B26], [@B46], [@B31], [@B29], [@B44]\]   1.104   0.907-1.343   0.325     83.5%, p\<0.001    1301             4G       0.765

DFS: disease free survival; HR: hazard ratio; OS: overall survival; *∗*Higgins *I*^*2*^ statistic.

###### 

Summary of miRs with altered expression, their potential targets, and pathways entered this study.

  miRNA   Expression   Potential targets                                Pathways                                                              Reference
  ------- ------------ ------------------------------------------------ --------------------------------------------------------------------- --------------------
  15b     Up           cyclin D1, MMP-3, NRP                            Angiogenesis, cell apoptosis, cell cycle progression, cell invasion   \[[@B75], [@B76]\]
  21      Up           BTG2, PDCD4, PTEN                                Cell apoptosis, invasion, migration, tumor growth                     \[[@B54]--[@B77]\]
  148a    Up           BIM, MIG6                                        Cell apoptosis                                                        \[[@B43]\]
  196     Up           HOXA7, HOXB8, HOXC8, HOXD8, I*κ*B*α*             Malignant transformation, tumorigenesis,                              \[[@B78]--[@B81]\]
  210     Up           FGFRL1, HIF-1a                                   Angiogenesis, cell migration, cell proliferation,                     \[[@B82]--[@B84]\]
  221     Up           AKT, p27Kipl, Growth factor signaling pathways   Cell proliferation, cell apoptosis, malignant phenotype               \[[@B85], [@B86]\]
  106a    Down         E2F1, TIMP-2                                     Cell apoptosis, cell invasion, cell proliferation,                    \[[@B60]\]
  124     Down         STAT3                                            T cell mediated clearance of glioma                                   \[[@B64]\]
  10b     Up           RhoC, uPA                                        Cell invasion, cell migration                                         \[[@B87], [@B88]\]
  17      Up or down   E2F1, TSP-1                                      Angiogenesis, cell growth, cell migration                             \[[@B65], [@B66]\]
  20a     Up           E2F1, TIMP-2                                     Cell invasion, cell proliferation                                     \[[@B89]--[@B92]\]
  155     Up           FOXO3a, p53                                      Cell invasion, cell migration                                         \[[@B93]--[@B95]\]
  182     Down         FOXO3, MITF-M                                    Cell migration, cell survival                                         \[[@B96]\]
  200b    Up or down   cyclin D1, EGFR, RND3                            Cell migration, epithelial-to mesenchymal transition                  \[[@B97], [@B98]\]
  222     Up           p27Kip1                                          Cell cycle progression, cell invasion, cell proliferation             \[[@B19], [@B86]\]

AKT, AKT serine/threonine kinase; BTG2, B cell translocation gene 2; E2F1, E2F transcription factor 1; EGFR, epidermal growth factor receptor; FGFRL1, fibroblast growth factor receptor-like 1; FOXO3a, forkhead box O3; HIF-1a, hypoxia-inducible factor 1a; HOX, homeobox; MIG6, mitogen-inducible gene 6; MITF-M, microphthalmia-associated transcription factor-M; MMP-3, matrix metalloproteinase-3; NRP, nitrogen regulatory protein; PDCD4, programmed cell death 4; PTEN, protein tyrosine phosphatase; RHOC, ras homolog family member C; RND3, rho family GTPase 3; STA3, signal transducers and activators of transcription; TIMP-2, tissue inhibitor of metalloproteinases-2; TSP-1, thrombospondin-1; uPA, urokinase-type plasminogen activator.
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